Using hymecromone to treat primary sclerosing cholangitis in adolescents and adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of hymecromone combined with standard care for treating adolescents and adults diagnosed with primary sclerosing cholangitis (PSC). The primary objective is to compare the efficacy of this combination therapy against standard care alone. Secondary objectives include assessing changes in alkaline phosphatase levels and various biomarkers related to PSC over a six-month treatment period. Participants will be monitored for improvements in liver function and disease markers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of primary sclerosing cholangitis confirmed by liver biopsy and/or imaging study
* If history of endoscopically confirmed inflammatory bowel disease, currently stable based on Mayo Score / Disease Activity Index (DAI) for Ulcerative Colitis Score ≤ 1, normal inflammatory markers (ESR, CRP and fecal calprotectin) and stable non-excluded medical therapy for at least 6 months

Exclusion Criteria:

* Currently receiving biologic therapies
* Known allergy to hymecromone
* Cholangiocarcinoma
* Pregnancy
* Serious liver disease

Where it's running

• Stanford Clinic
  Redwood City, California, United States Recruiting
• Stanford Clinic
  Stanford, California, United States Recruiting

Study contacts

• Principal investigator: Aparna Goel, MD — Stanford University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Elafibranor for adults with primary sclerosing cholangitis

  This trial will see if taking elafibranor once daily helps adults with primary sclerosing cholangitis compared with a placebo.

  Recruiting at 41 sites Phase 3 Ipsen · Chandler, Arizona and 230 other locations · NCT07387549

• TAK-781 treatment in healthy adults and people with non-cirrhotic primary sclerosing cholangitis

  This study will test whether TAK-781 is safe and tolerable in healthy adults and in people with non-cirrhotic primary sclerosing cholangitis while measuring how the body handles and responds to the drug.

  Recruiting Phase 1 Takeda · Salt Lake City, Utah · NCT07229911

• Preventing recurrence of primary sclerosing cholangitis after liver transplantation

  This study is testing if a daily medication called fenofibrate can help prevent primary sclerosing cholangitis from coming back in people who have had a liver transplant.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06905054

• LEOPARD: Predicting liver transplant dropout with AI in European patients

  This project tests new AI-based models to predict which liver transplant candidates are at highest risk of dropout or death while on the waitlist.

  Recruiting at 4 sites Assistance Publique - Hôpitaux de Paris · Ghent, Belgium and 7 other locations · NCT06723275

• Collecting data to improve liver transplantation predictions

  This study is trying to use AI to better predict which liver transplant candidates are at risk of dropping out of the waitlist, so that more people can get fair access to transplants across Europe.

  Recruiting at 53 sites Assistance Publique - Hôpitaux de Paris · Vienna and 52 other locations · NCT06675604

• Identifying liver disease-specific gut microbiomes

  This study is trying to find out if certain gut bacteria are linked to chronic liver diseases in adults, including autoimmune hepatitis and primary biliary cholangitis, by analyzing blood and stool samples from patients and their household members.

  Recruiting Chungnam National University Hospital · Daejeon, Jung-gu · NCT06519162

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.